Evidence map›Paper›PMID 26826536›Full record

ArticleHipertension y riesgo vascular

[Cardiovascular risk study in patients with renin-angiotensin system blockade by means of the proteone of circulating extracellular vesicles].

F de la Cuesta, M Baldan-Martin, L Mourino-Alvarez, T Sastre-Oliva, G Alvarez-Llamas, L Gonzalez-Calero, G Ruiz-Hurtado, J Segura, F Vivanco, L M Ruilope and 1 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Hipertension y riesgo vascular. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03887416. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03887416 phase4unknown status

Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes

Ran2019Enrolled225Registered outcomes4Posted comparisons0ConditionsType2 DiabetesArmsDapagliflozin 10 MG Oral Tablet [Farxiga], Placebo Oral Tablet
Open the trial in the graph
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

F de la CuestaLaboratorio de Fisiopatología Vascular, Hospital Nacional de Parapléjicos (HNP), Servicio de Salud de Castilla la Mancha (SESCAM), Toledo, España. Electronic address: ferdela@sescam.jccm.es.
M Baldan-MartinLaboratorio de Fisiopatología Vascular, Hospital Nacional de Parapléjicos (HNP), Servicio de Salud de Castilla la Mancha (SESCAM), Toledo, España.
L Mourino-AlvarezLaboratorio de Fisiopatología Vascular, Hospital Nacional de Parapléjicos (HNP), Servicio de Salud de Castilla la Mancha (SESCAM), Toledo, España.
T Sastre-OlivaLaboratorio de Fisiopatología Vascular, Hospital Nacional de Parapléjicos (HNP), Servicio de Salud de Castilla la Mancha (SESCAM), Toledo, España.
G Alvarez-LlamasDepartamento de Inmunología, IIS-Fundación Jiménez Díaz, Madrid, España.
L Gonzalez-CaleroDepartamento de Inmunología, IIS-Fundación Jiménez Díaz, Madrid, España.
G Ruiz-HurtadoDepartamento de Riesgo Cardiovascular e Hipertensión, IIS-Hospital 12 de Octubre, Madrid, España.
J SeguraUnidad de Hipertensión, Hospital 12 de Octubre, Madrid, España.
F VivancoDepartamento de Inmunología, IIS-Fundación Jiménez Díaz, Madrid, España.
L M RuilopeDepartamento de Riesgo Cardiovascular e Hipertensión, IIS-Hospital 12 de Octubre, Madrid, España.
M G BarderasLaboratorio de Fisiopatología Vascular, Hospital Nacional de Parapléjicos (HNP), Servicio de Salud de Castilla la Mancha (SESCAM), Toledo, España.
Servicio de Salud de Castilla La Mancha · ESHospital Universitario Fundación Jiménez Díaz · ESResearch Institute Hospital 12 de Octubre · ESHospital Universitario 12 De Octubre · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionExtracellular vesicles (EVs) are released to the bloodstream by certain cell types due to transport, activation and cell death processes. Blood count of EVs from platelet and endothelial origin has been proved to be a cardiovascular risk biomarker. Thus, EVs proteome might reflect the underlying cellular processes in hypertensive patients with albuminuria. MATERIAL AND

methodsProtein content of circulating EVs was analyzed by liquid chromatography coupled to mass spectrometry. EVs were isolated by an ultracentrifugation protocol optimized in order to avoid contamination by blood plasma proteins. Purity of the isolated fraction was verified by electronic and confocal microscopy, and by flow cytometry.

resultsWe hereby show a method to isolate circulating EVs from hypertensive patients with/without albuminuria with high yield and purity. Besides, we provide a reference proteome of the EVs of these patients, composed of 2,463 proteins, and prove that the proteins carried by these vesicles are associated with crucial processes involved in the inherent cardiovascular risk.

conclusionThe proteome of circulating EVs is an interesting source of indicators in the evaluation of cardiovascular risk in hypertensive patients with renin-angiotensin system blockage.

Indexed as

Extracellular VesiclesProteomeRenin-Angiotensin SystemBlood PlateletsBlood ProteinsCardiovascular DiseasesChromatography, LiquidFlow CytometryHumansRisk FactorsSecretory VesiclesTransport VesiclesBlood ProteinsProteomeAlbuminuriaBloqueo sistema renina-angiotensinaExtracellular vesiclesProteómicaProteomicsRenin-angiotensin system blockageVesículas extracelulares

Identifiers

PMID26826536
OpenAlexW1684234429

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.